572
Participants
Start Date
April 2, 2025
Primary Completion Date
January 17, 2031
Study Completion Date
January 17, 2031
Tacrolimus (Tac)
Tablet or intravenously (IV)
Methotrexate (MTX)
Intravenously (IV)
Ruxolitinib (Rux)
Tablet
Cyclophosphamide
Intravenously (IV)
Mycophenolate mofetil (MMF)
Tablet or intravenously (IV)
RECRUITING
Mount Sinai Hospital, New York
RECRUITING
Memorial Sloan Kettering, New York
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Virginia Commonwealth University, North Hospital, Richmond
RECRUITING
University of North Carolina At Chapel Hill, Chapel Hill
RECRUITING
Duke University Medical Center, Durham
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Blood and Marrow Transplant Group of Georgia, Atlanta
RECRUITING
University of Miami, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
Vanderbilt Medical Center, Nashville
RECRUITING
Ohio State University, Columbus
RECRUITING
Indiana University Cancer Center, Indianapolis
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
Henry Ford Hospital, Detroit
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Wisconsin, Madison
RECRUITING
Washington University, St Louis
RECRUITING
University of Kansas Hospital Authority, Kansas City
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
Stanford Cancer Center, Palo Alto
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Fred Hutchinson Cancer Research Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
Lead Sponsor
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Institutes of Health (NIH)
NIH
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Cancer Institute (NCI)
NIH
Incyte Corporation
INDUSTRY